KRASmutations in blood circulating cell-free DNA: a pancreatic cancer case-control

Capocaccia, 2009, EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary, Eur J Cancer, 45, 931, 10.1016/j.ejca.2008.11.018

Forman, 2009, Cancer survival in England and the influence of early diagnosis: what can we learn from recent EUROCARE results?, Br J Cancer, 101, S102

Tseng, 2014, Outcomes in operative management of pancreatic cancer, J Surg Oncol, 110, 592, 10.1002/jso.23744

Malafa, 2008, Early detection of pancreatic cancer: why, who, and how to screen, Cancer Control, 15, 280, 10.1177/107327480801500402

Siriwardena, 2007, Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer, Eur. J. Surg. Oncol, 33, 266, 10.1016/j.ejso.2006.10.004

Liu, 2014, Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis, Tumour Biol, 35, 7459, 10.1007/s13277-014-1995-9

Chamberlain, 2012, The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal, J Gastrointest Oncol, 3, 105

Pantel, 2011, Cell-free nucleic acids as biomarkers in cancer patients, Nat Rev Cancer, 11, 426, 10.1038/nrc3066

Partensky, 2013, Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?, Pancreas, 42, 729, 10.1097/MPA.0b013e318288107a

Kern, 1995, K-ras mutation and pancreatic adenocarcinoma, Int J Pancreatol, 18, 1, 10.1007/BF02825415

Goggins, 2012, Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia, Gastroenterology, 142, 730, 10.1053/j.gastro.2011.12.042

Hruban, 2005, Precursors to invasive pancreatic cancer, Adv Anat Pathol, 12, 81, 10.1097/01.pap.0000155055.14238.25

Hebrok, 2010, KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma, Nat Rev Cancer, 10, 683, 10.1038/nrc2899

Farre, 1999, K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance, J Clin Oncol, 17, 578, 10.1200/JCO.1999.17.2.578

Xuezhi, 2002, A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis, Pancreas, 25, 336, 10.1097/00006676-200211000-00003

Li, 2007, K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking, Pancreas, 34, 55, 10.1097/01.mpa.0000246665.68869.d4

Puig, 2002, Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA, Br J Cancer, 87, 551, 10.1038/sj.bjc.6600475

Stroun, 1998, A prospective study of K-ras mutations in the plasma of pancreatic cancer patients, Clin Cancer Res, 4, 271

Monden, 1998, Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features, Clin Cancer Res, 4, 1527

Oettle, 2009, Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9, Pancreas, 38, 534, 10.1097/MPA.0b013e31819f6376

Gonzalez-Sastre, 2006, Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer, Clin Chem, 52, 1448, 10.1373/clinchem.2006.067140

White, 2015, Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients, Nat Commun, 6, 7686, 10.1038/ncomms8686

Shimada, 2015, Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer, Sci Rep, 5, 18425, 10.1038/srep18425

Smaaland, 2016, Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer, Mol Oncol, 10, 635, 10.1016/j.molonc.2015.11.012

Nakao, 2004, Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients, J Gastroenterol, 39, 56, 10.1007/s00535-003-1245-1

Bardelli, 2014, Detection of circulating tumor DNA in early- and late-stage human malignancies, Sci Transl Med, 6, 224ra24, 10.1126/scitranslmed.3007094

Margery, 2014, Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002, Clin Cancer Res, 20, 4613, 10.1158/1078-0432.CCR-13-3063

Becq, 2013, Analysis of circulating tumor DNA to monitor metastatic breast cancer, N Engl J Med, 368, 1199, 10.1056/NEJMoa1213261

Diaz, 2010, Development of personalized tumor biomarkers using massively parallel sequencing, Sci Transl Med, 2, 20ra14

Patel, 2012, Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing, Cancer Res, 72, 3492, 10.1158/0008-5472.CAN-11-4037

Alizadeh, 2014, An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, 20, 548, 10.1038/nm.3519

Lo, 2015, Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients, Proc Natl Acad Sci U S A, 112

Caldas, 2012, Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA, Sci Transl Med, 4, 136ra68

Gardiner, 2012, Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes, Nature, 491, 399, 10.1038/nature11547

Fadlullah, 2015, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518, 495, 10.1038/nature14169

Hemsley, 2010, International network of cancer genome projects, Nature, 464, 993, 10.1038/nature08987

Thierry, 2013, Circulating cell free DNA: Preanalytical considerations, Clin Chim Acta, 424, 222, 10.1016/j.cca.2013.05.022

Bibeau, 2014, Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, 20, 430, 10.1038/nm.3511

Yong, 2014, Cancer biomarkers: Written in blood, Nature, 511, 524, 10.1038/511524a

Kinzler, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122

Malaveille, 2006, TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study, Cancer Res, 66, 6871, 10.1158/0008-5472.CAN-05-4556

Risques, 2016, Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues, Proc Natl Acad Sci U S A

Holcatova, 2016, Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer, EBioMedicine, 117

Casanova, 2012, Keratinocytic epidermal nevi are associated with mosaic RAS mutations, J Med Genet, 49, 249, 10.1136/jmedgenet-2011-100637

Groesser, 2013, Mosaic RASopathies, Cell Cycle, 12, 43, 10.4161/cc.23108

Yuan, 2011, Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer, J Dig Dis, 12, 131, 10.1111/j.1751-2980.2011.00488.x

Fraga, 2015, Glypican-1 identifies cancer exosomes and detects early pancreatic cancer, Nature, 523, 177, 10.1038/nature14581

Goggins, 2013, Novel methylation biomarker panel for the early detection of pancreatic cancer, Clin Cancer Res, 19, 6544, 10.1158/1078-0432.CCR-12-3224

Zen, 2012, Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer, Clin Chem, 58, 610, 10.1373/clinchem.2011.172767

Moskal, 2014, Physical activity and risk of pancreatic cancer in a central European multicenter case-control study, Cancer Causes Control, 25, 669, 10.1007/s10552-014-0370-x

Scelo, 2011, Body mass index and body size in early adulthood and risk of pancreatic cancer in a central European multicenter case-control study, Int J Cancer, 129, 2875, 10.1002/ijc.25959

Huggett, 2014, Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification, Anal Bioanal Chem, 406, 6499, 10.1007/s00216-014-7835-3

Steinberg, 1990, The clinical utility of the CA 19-9 tumor-associated antigen, Am J Gastroenterol, 85, 350

Heritier, 2014, Robust inference in the negative binomial regression model with an application to falls data, Biometrics, 70, 920, 10.1111/biom.12212